Articaine and Epinephrine for Newborns (Neonates, 0 to 28 Days)
No standard dose
The label gives no dose for newborns. It covers only ages 4 and older.
"Safety and effectiveness of SEPTOCAINE in pediatric patients below the age of 4 years have not been established." (label 8.4)
Articaine and Epinephrine for Infants (1 to 12 Months)
No standard dose
The label gives no dose for infants. It covers only ages 4 and older.
"Safety and effectiveness of SEPTOCAINE in pediatric patients below the age of 4 years have not been established." (label 8.4)
Articaine and Epinephrine for Children 1 to 3 Years
No standard dose
The label gives no dose under 4 years.
"Safety and effectiveness of SEPTOCAINE in pediatric patients below the age of 4 years have not been established." (label 8.4)
Articaine and Epinephrine Dose for Children (4 to 16)
Max 7 mg/kg articaine
Special situations, children
With kidney disease
No adjustment in the label. Not studied.
"No studies have been performed in patients with renal or liver impairment." (label 2.3)
With liver disease
No adjustment in the label. Use caution in severe liver disease.
"Exercise caution when using SEPTOCAINE in patients with severe liver disease." (label 2.3)
On dialysis
Not covered by the label.
The label does not mention dialysis.
With heart or blood vessel disease
No set dose in the label. Use the least epinephrine possible and aspirate before every injection. A conservative epinephrine limit is applied below. It is expert guidance, not a label or guideline limit.
"The minimum possible amount of vasoconstrictor should be used." (American Heart Association, quoted in label 5.3) · "A dose of 40 µg ... is the most conservative and frequently cited dose limitation for epinephrine in patients with significant cardiovascular disease. It should be clarified that this guideline more accurately reflects 30-minute time periods, not appointments." (Becker 2006)
Taking interacting medicines
No dose change in the label. Avoid the combination if possible, otherwise monitor closely. MAO inhibitors, nonselective beta blockers and tricyclic antidepressants can cause severe, prolonged high blood pressure. Phenothiazines and butyrophenones can reduce or reverse the effect of epinephrine.
"Concurrent use of these agents should be avoided; however, in situations when concurrent therapy is necessary, careful patient monitoring is essential." (label 7)
At risk of methemoglobinemia
No dose change in the label. Monitor closely with G6PD deficiency, congenital or idiopathic methemoglobinemia, heart or lung compromise, or other oxidizing drugs, including other local anesthetics, nitrates, dapsone and sulfonamides.
"If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended." (label 5.4, Table 5 in label 7)
Sulfite allergy or asthma
Contains sodium metabisulfite, a sulfite. It can cause allergic-type reactions, more often in people with asthma.
"Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people." (label 5.5)
In pregnancy
No dose change in the label. Use only if the benefit justifies the risk.
"SEPTOCAINE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus." (label 8.1)
While breastfeeding
No dose change in the label. The patient may pump and discard milk for about 4 hours after the injection, then resume.
"nursing mothers may choose to pump and discard breast milk for approximately 4 hours (based on plasma half life) following an injection of SEPTOCAINE ... and then resume breastfeeding." (label 8.3)
Articaine and Epinephrine Dose for Adults (17 to 64)
Max 7 mg/kg articaine in healthy adults
Special situations, adults
With kidney disease
No adjustment in the label. Not studied.
"No studies have been performed in patients with renal or liver impairment." (label 2.3)
With liver disease
No adjustment in the label. Use caution in severe liver disease.
"Exercise caution when using SEPTOCAINE in patients with severe liver disease." (label 2.3)
On dialysis
Not covered by the label.
The label does not mention dialysis.
With heart or blood vessel disease
No set dose in the label. Use the least epinephrine possible and aspirate before every injection. A conservative epinephrine limit is applied below. It is expert guidance, not a label or guideline limit.
"The minimum possible amount of vasoconstrictor should be used." (American Heart Association, quoted in label 5.3) · "A dose of 40 µg ... is the most conservative and frequently cited dose limitation for epinephrine in patients with significant cardiovascular disease. It should be clarified that this guideline more accurately reflects 30-minute time periods, not appointments." (Becker 2006)
Taking interacting medicines
No dose change in the label. Avoid the combination if possible, otherwise monitor closely. MAO inhibitors, nonselective beta blockers and tricyclic antidepressants can cause severe, prolonged high blood pressure. Phenothiazines and butyrophenones can reduce or reverse the effect of epinephrine.
"Concurrent use of these agents should be avoided; however, in situations when concurrent therapy is necessary, careful patient monitoring is essential." (label 7)
At risk of methemoglobinemia
No dose change in the label. Monitor closely with G6PD deficiency, congenital or idiopathic methemoglobinemia, heart or lung compromise, or other oxidizing drugs, including other local anesthetics, nitrates, dapsone and sulfonamides.
"If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended." (label 5.4, Table 5 in label 7)
Sulfite allergy or asthma
Contains sodium metabisulfite, a sulfite. It can cause allergic-type reactions, more often in people with asthma.
"Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people." (label 5.5)
In pregnancy
No dose change in the label. Use only if the benefit justifies the risk.
"SEPTOCAINE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus." (label 8.1)
While breastfeeding
No dose change in the label. The patient may pump and discard milk for about 4 hours after the injection, then resume.
"nursing mothers may choose to pump and discard breast milk for approximately 4 hours (based on plasma half life) following an injection of SEPTOCAINE ... and then resume breastfeeding." (label 8.3)
Articaine and Epinephrine Dose for Older Adults (65 and Older)
Max 7 mg/kg articaine, a lower dose may be needed
What the label says about age 65 and older
No set dose cut. Use the adult max, and give less when the patient is frail or unwell. Some older patients may be more sensitive.
"Lower dosages or dosage reduction may be required in debilitated patients, acutely ill patients, elderly patients..." (label 2.3)
"...greater sensitivity of some older individuals cannot be ruled out." (label 8.5)
Doses given in the label's studies (not limits): ages 65 to 75, 0.43 to 4.76 mg/kg; 75 and older, 0.78 to 4.76 mg/kg (label 8.5).
Special situations, older adults
With kidney disease
No adjustment in the label. Not studied.
"No studies have been performed in patients with renal or liver impairment." (label 2.3)
With liver disease
No adjustment in the label. Use caution in severe liver disease.
"Exercise caution when using SEPTOCAINE in patients with severe liver disease." (label 2.3)
On dialysis
Not covered by the label.
The label does not mention dialysis.
With heart or blood vessel disease
No set dose in the label. Use the least epinephrine possible and aspirate before every injection. A conservative epinephrine limit is applied below. It is expert guidance, not a label or guideline limit.
"The minimum possible amount of vasoconstrictor should be used." (American Heart Association, quoted in label 5.3) · "A dose of 40 µg ... is the most conservative and frequently cited dose limitation for epinephrine in patients with significant cardiovascular disease. It should be clarified that this guideline more accurately reflects 30-minute time periods, not appointments." (Becker 2006)
Taking interacting medicines
No dose change in the label. Avoid the combination if possible, otherwise monitor closely. MAO inhibitors, nonselective beta blockers and tricyclic antidepressants can cause severe, prolonged high blood pressure. Phenothiazines and butyrophenones can reduce or reverse the effect of epinephrine.
"Concurrent use of these agents should be avoided; however, in situations when concurrent therapy is necessary, careful patient monitoring is essential." (label 7)
At risk of methemoglobinemia
No dose change in the label. Monitor closely with G6PD deficiency, congenital or idiopathic methemoglobinemia, heart or lung compromise, or other oxidizing drugs, including other local anesthetics, nitrates, dapsone and sulfonamides.
"If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended." (label 5.4, Table 5 in label 7)
Sulfite allergy or asthma
Contains sodium metabisulfite, a sulfite. It can cause allergic-type reactions, more often in people with asthma.
"Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people." (label 5.5)
Sources
FDA label, Oct 2024
- Label
- Septocaine and Epinephrine, Septodont (DailyMed)
- Version
- 14, published Oct 25, 2024
- Retrieved
- Nov 15, 2026
- Also used
- Becker and Reed, Anesthesia Progress 2006: the additive rule for two anesthetics, and the 0.04 mg epinephrine limit with heart disease (not an AHA limit).
- Reviewed
- Nov 15, 2026, by the site pharmacist
- Not used
- 2007 label (product 12862-1050, no longer in the FDA NDC Directory). Same 7 mg/kg max.
Label text used
2.2: "The maximum recommended dosage of SEPTOCAINE is 7 mg/kg of articaine and 0.0017mg/kg of epinephrine (equivalent to 0.175 mL/kg for either product presentation...)." Same text for adults and for ages 4 to 16.
3: "Articaine hydrochloride 4% (68 mg/1.7mL) (40 mg/mL)"
2.1: "In all cases, administer the lowest dosage that will produce the desired result."
2.3, 8.1, 8.3, 8.4: quoted in each section above.